| ￥2000 | |
| Z05261-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | |
| Protein Construction |
|
|
| Purity | > 95% as determined by BisTris PAGE | |
| Endotoxin Level | Less than 0.1EU per μg by the LAL method. | |
| Biological Activity | Measured in a cell proliferation assay using TF‑1 human erythroleukemic cells. Test result was comparable to standard batch. | |
| Expression System | HEK293 | |
| Theoretical Molecular Weight | 18.39 kDa | |
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 35-45 kDa based on Bis-Tris PAGE result. | |
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | |
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | |
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
| Target Background | Erythropoietin (EPO) is a circulating hormone conventionally considered to be responsible for erythropoiesis. In addition to facilitating red blood cell production, EPO has pluripotent potential, such as for cognition improvement, neurogenesis, and anti-fibrotic, anti-apoptotic, anti-oxidative, and anti-inflammatory effects. |
| Synonyms | EPO; Erythropoietin; EP; MVCD2; Epoetin |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
